NGNE · Neurogene Inc. · Documents

Jun 3

Current report 8-K

Regulation FD disclosure

May 10

Current report 8-K

Financial results

May 10

Quarterly report 10-Q FY2024 Q1, ended Mar 31

Quarterly report for FY2024 Q1

Net loss $16.92M Diluted EPS -$1.00

May 7

Current report 8-K

Regulation FD disclosure

Apr 26

Proxy statement DEF 14A

Proxy statement

Apr 26

Proxy statement DEFA14A

Proxy statement

Apr 26

Annual report to holders ARS

Annual report to holders

Apr 25

Current report 8-K Events of Apr 19

Director or officer change, or executive pay

Apr 22

Current report 8-K

Regulation FD disclosure

Apr 2

Current report 8-K Events of Apr 1

Director or officer change, or executive pay

Mar 18

Current report 8-K

Financial results

Mar 18

Annual report 10-K FY2023, ended Dec 31

Annual report for FY2023

Net loss $36.32M

Mar 4

Current report 8-K

Regulation FD disclosure

Feb 21

Current report 8-K Events of Feb 15

Director or officer change, or executive pay

Jan 5

Current report 8-K

Regulation FD disclosure

Dec 19

Current report 8-K Events of Dec 13

Entered into a material agreement, Completed an acquisition or sale of assets, Change to shareholders' rights, Change in control, Director or officer change, or executive pay, Charter or bylaw amendment, or fiscal year change, Code of ethics change or waiver, Shareholder vote results, Shareholder director nominations, Regulation FD disclosure

Dec 6

Current report 8-K

Other events

Dec 4

Current report 8-K Events of Nov 30

Other events

Nov 14

Quarterly report 10-Q FY2023 Q3, ended Sep 30

Quarterly report for FY2023 Q3

Net loss $4.53M Diluted EPS -$0.41

Nov 8

Registration statement S-4/A

Registration statement

Oct 18

Registration statement S-4/A

Registration statement

Sep 28

Registration statement S-4/A

Registration statement

Sep 22

Current report 8-K

Change to shareholders' rights, Charter or bylaw amendment, or fiscal year change, Other events

Aug 21

Registration statement S-4

Registration statement

Aug 10

Quarterly report 10-Q FY2023 Q2, ended Jun 30

Quarterly report for FY2023 Q2

Net loss $2.09M Diluted EPS -$0.04

Jul 18

Current report 8-K Events of Jul 17

Entered into a material agreement, Unregistered sale of equity, Change in control, Director or officer change, or executive pay, Regulation FD disclosure

Jun 12

Current report 8-K Events of Jun 8

Shareholder vote results

May 8

Quarterly report 10-Q FY2023 Q1, ended Mar 31

Quarterly report for FY2023 Q1

Net loss $14.2M Diluted EPS -$0.26

Apr 27

Proxy statement DEF 14A Meeting Jun 8, 2023

Proxy statement

Apr 27

Annual report to holders ARS

Annual report to holders

Apr 27

Proxy statement DEFA14A

Proxy statement

Apr 14

Proxy statement PRE 14A Meeting Jun 8, 2023

Proxy statement

Apr 3

Current report 8-K

Director or officer change, or executive pay

Mar 20

Annual report 10-K FY2022, ended Dec 31

Annual report for FY2022

Net loss $57.56M Diluted EPS -$1.04

Mar 10

Current report 8-K Events of Mar 6

Exit or restructuring costs, Director or officer change, or executive pay

Mar 8

Current report 8-K

Regulation FD disclosure

Jan 23

Current report 8-K/A Events of Nov 30

Charter or bylaw amendment, or fiscal year change

Nov 30

Current report 8-K

Charter or bylaw amendment, or fiscal year change

Nov 14

Current report 8-K

Financial results, Regulation FD disclosure

Nov 14

Quarterly report 10-Q FY2022 Q3, ended Sep 30

Quarterly report for FY2022 Q3

Net loss $13.07M Diluted EPS -$0.24

Oct 31

Current report 8-K Events of Oct 26

Delisting notice or listing transfer

Aug 9

Current report 8-K

Financial results, Regulation FD disclosure

Aug 9

Quarterly report 10-Q FY2022 Q2, ended Jun 30

Quarterly report for FY2022 Q2

Net loss $15.69M Diluted EPS -$0.28

Jul 27

Current report 8-K

Regulation FD disclosure

May 16

Current report 8-K Events of May 12

Shareholder vote results

May 9

Current report 8-K

Financial results

May 9

Quarterly report 10-Q FY2022 Q1, ended Mar 31

Quarterly report for FY2022 Q1

Net loss $15.35M Diluted EPS -$0.28

May 9

Registration statement S-3

Registration statement

Mar 31

Proxy statement DEF 14A Meeting May 12, 2022

Proxy statement

Mar 31

Proxy statement DEFA14A

Proxy statement